Shots:

• The SURPASS-4 study evaluates the efficacy & safety of tirzepatide (5/10/15mg) vs insulin glargine in 2002 adults in a ratio (1:1:1:3) with T2D inadequately controlled with 1 & up to 3 oral antihyperglycemic medications who have increased CV risk
• The study met its 1EPs & 2EPs i.e.- superior A1C & body weight reductions for both estimands @52wks. A1C reduction (-2.24% / -2.43%/ -2.58% vs -1.44%); weight reduction (-7.1/ -9.5/ -11.7kg vs +1.9 kg); patients achieving A1C <7% (81%/ 88%/ 91% vs 51%); patients achieving A1C <5.7% (23%/ 33%/ 43% vs 3%) respectively
• Additionally- the overall safety profile was consistent with safety results @52wks. & no new findings were observed @~104 weeks.

  | Ref: PR Newswire | Image: The Indian Express